[ACST] Acasti Pharma, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 14.14 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.33 Change: 0.17 (14.65%)
Ext. hours: Change: 0 (0%)

chart ACST

Refresh chart

Strongest Trends Summary For ACST

ACST is in the long-term down -97% below S&P in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

Fundamental Ratios
Shares Outstanding10.71 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week3.1 Low 52 week0.63 Last close0.71 Last change1.59%
RSI36.35 Average true range0.04 Beta0.3 Volume4.94 M
Simple moving average 20 days-2.49% Simple moving average 50 days-23.16% Simple moving average 200 days-39.8%
Performance Data
Performance Week7.92% Performance Month-34.26% Performance Quart-31.73% Performance Half-44.96%
Performance Year-43.2% Performance Year-to-date-24.69% Volatility daily6.55% Volatility weekly14.65%
Volatility monthly30.03% Volatility yearly104.04% Relative Volume5202.7% Average Volume196.58 K
New High New Low


2019-03-13 08:30:00 | Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

2019-02-21 09:15:00 | Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

2019-02-14 14:57:21 | Acasti: Fiscal 3Q Earnings Snapshot

2019-02-14 08:05:00 | Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

2019-02-08 08:00:00 | Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs

2019-01-09 08:00:00 | Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

2018-12-31 08:00:00 | Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients >20% Have Completed Their 6 Month Treatment Plan

2018-12-28 09:55:02 | Generic Industry on Path to Recovery: 3 Hot Picks for 2019

2018-12-20 08:00:00 | Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

2018-11-27 07:00:00 | Acasti Pharma to Present at the 11th Annual LD Micro Main Event

2018-11-14 08:53:13 | Acasti: Fiscal 2Q Earnings Snapshot

2018-11-14 08:00:00 | Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

2018-11-07 08:00:00 | Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

2018-10-23 09:00:11 | Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option

2018-10-11 07:30:00 | Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

2018-10-10 08:05:00 | Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review

2018-10-04 09:35:40 | Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares

2018-10-04 07:59:50 | The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

2018-10-03 16:23:12 | Acasti Pharma Announces Public Equity Offering

2018-10-03 16:23:11 | Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares

2018-10-02 09:10:25 | The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

2018-10-01 17:00:00 | Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

2018-09-28 08:17:00 | Today’s Research Reports on Stocks to Watch: Achieve Life Sciences and Acasti Pharma

2018-09-24 08:00:00 | Acasti Pharma Appoints Jean-François Boily as Vice President of Finance

2018-09-18 08:52:02 | Acasti Pharma Provides Clinical and Market Update

2018-08-29 16:05:00 | Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

2018-08-14 13:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019

2018-08-14 08:39:31 | Acasti: 2Q Earnings Snapshot

2018-07-31 17:09:05 | Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan

2018-07-24 09:15:11 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-24 07:00:00 | Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office

2018-07-02 17:00:00 | Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures

2018-06-28 08:26:54 | Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

2018-06-27 17:00:00 | Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018

2018-06-11 20:07:54 | Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis

2018-06-06 07:00:00 | Acasti Pharma to Present at the XVIIIth International Symposium on Atherosclerosis

2018-06-04 07:00:00 | Acasti Pharma Appoints Brian Groch as Chief Commercial Officer

2018-05-18 07:00:00 | Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States

2018-05-14 13:23:16 | Acasti Pharma Announces Full Exercise of Over-Allotment Option

2018-05-09 12:42:27 | Acasti Pharma Announces Closing of $10 Million Underwritten Offering

2018-04-27 08:00:00 | Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee

2018-04-24 12:17:36 | Acasti Pharma Prices $10 Million Underwritten Offering

2018-04-23 16:11:03 | Acasti Pharma Announces Overnight Marketed Public Unit Offering

2018-04-02 08:00:00 | Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

2018-03-14 08:00:00 | Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

2018-02-14 05:01:15 | Acasti reports 4Q loss

2018-02-13 17:00:00 | Acasti Pharma Reports Third Quarter FY 2018 Financial Results

2018-01-22 17:05:00 | Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

2018-01-16 08:00:00 | Acasti Pharma Announces Change to Board of Directors